W
hile some low-grade pediatric gliomas may be cured with resection, many patients harbor tumors that cannot be completely excised in a safe fashion. This is especially the case when tumors present in the brainstem, eloquent cortex, or deep brain nuclei. 4, 15 In addition, despite attempts at complete resection when deemed safe, there are frequently small residual components of tumors. Although the natural history of such lesions is not clear, some tumors do progress. 2 Furthermore, recurrence may develop despite the imaging appearance of complete resection, especially in cases of nonpilocytic gliomas. The management of these lesions remains challenging. 11, 15 Both chemotherapy and fractionated radiation therapy have produced variable results. 4, 6, 10, 14, 19, 20 Other authors have reported the successful treatment of these lesions using GKS. 1, 7, 12, 13, 23, 24, 26 This modality has the potential benefit of limiting the morbidity associated with fractionated external-beam radiotherapy while achieving tumor control and neurologi-cal preservation. In the present article, we evaluate the results from our single-center experience in using GKS to treat pediatric gliomas.
Methods
Our radiosurgical database was searched to identify all patients 18 years of age and younger at the time of GKS for any lesion categorized as glioma. This included all cranial lesions histologically proven or suspected to be pilocytic astrocytomas based on imaging as well as nonpilocytic glial tumors. The tumors that were considered gliomas without basis in histological diagnosis were largely brainstem lesions with typical features of a lowgrade brainstem glioma and with a clinical history and neurological status consistent with such a lesion. The study was approved by the University of Virginia Health Sciences internal review board.
The following baseline clinical variables were recorded: patient age, sex, year of treatment, tumor volume, KPS score, symptoms at presentation, symptom duration at the time of treatment, pathology (if known), tumor location (brainstem, cerebellum, thalamus, or supratentorial cortex), presence of tumor enhancement, method of histopathological diagnosis (none, biopsy, or resection), timing of GKS (primary treatment or after resection with residual tumor or recurrence), history of increasing tumor size, and previous external-beam radiation therapy. Treatment variables recorded included maximal tumor radiation dose, margin tumor dose, and number of isocenters. Outcome variables included overall survival, progression-free survival, maximum change in tumor volume, the interval until tumor volume decrease was noted, and increase in peritumoral edema or increased enhancement. Progression was considered to have occurred if the absolute size of the tumor, including both solid and cystic components, increased in size consistently. Patients with increases in the solid or cystic components who required operative intervention were also considered to have evidence of progression.
Gamma Knife Surgery Technique
The GKS procedure used in our institution has been described elsewhere. 9 In pediatric patients, it is our standard practice to perform frame placement and radiosurgical treatment after induction of general anesthesia. Magnetic resonance imaging was used for all cases except 2 treated in 1989, in which CT was used. Treatment was performed using the Leksell Gamma Unit, model U, and planning was performed using the KULA and subsequently the GammaPlan software (Elekta Instruments, Inc.). All patients were discharged from the hospital within 24 hours of the procedure.
Follow-Up Evaluation
As part of the routine follow-up care after radiosurgery, MRI was planned every 3 months for the 1st year and every 6 months thereafter or if new symptoms developed. Follow up MR images were reviewed by a neurosurgeon and a neuroradiologist at our institution. Tumor volumes were calculated using previously described volumetric analysis. 22 Other changes were also noted, specifically the presence of peritumoral edema. Whenever possible, patients were examined in follow-up visits by the treating neurosurgeon. However, as not all patients were able to return to our institution for clinical follow-up, some clinical follow-up information was obtained from local physicians and/or the patients and their families.
Statistical Analysis
All statistical analyses were performed using standard, commercially available software (SPSS Version 19, IBM). The Fisher exact test was used for binary variables, and nonparametric independent t-tests were performed for continuous variables. Logistic regression was used for multivariate analysis. Progression-free survival was evaluated using a Kaplan-Meier survival curve. Significance for all analyses was set at p < 0.05.
Results

Patient and Treatment Characteristics
Between 1989 and 2011, 13 male and 11 female patients (median age 11 years, range 4-18 years) with gliomas were treated. ). Prior to GKS, 3 patients had undergone external-beam radiotherapy. Symptoms were categorized as motor symptoms, cranial nerve deficits, cerebellar symptoms, hydrocephalus, headache, seizure, and other. The median KPS score at the time of treatment was 90 (range 80-100).
Tumors were treated with a median maximum dose of 36 Gy (range 13-40 Gy), the median marginal dose was 15 Gy (range 4-20 Gy), and the median of number of isocenters was 3 (range 1-9). Lower margin doses were used in patients who had previously undergone fractionated radiotherapy and in some patients with brainstem lesions out of concern for toxicity based on the experience of others 3, 16 (Table 1) .
Imaging and Clinical Outcome
The median MRI follow-up was 74 months (range 9-207 months), and the median clinical follow-up was 144 months (range 9-252 months). At last follow-up, 23 (96%) of the 24 patients were alive. Progression-free survival at last follow-up was achieved in 20 patients (83%). Progression was seen on MRI in 4 patients (17%), with 3 patients requiring urgent repeat resection and 1 patient dying ( 1). The median maximal decrease in tumor volume was 71% (range 100% decrease to 518% increase). In 18 patients (75%) there was a decrease in tumor size of at least 50%, and in 5 patients (21%) there was complete tumor resolution (Fig. 2) . In patients in whom the tumors decreased in size, the median interval before a decrease in size was achieved was 12.5 months (range 3-46 months). In addition to the 4 patients in whom tumor progression was documented, there were 3 patients in whom a transient increase in T2-weighted signal changes was noted on the 6-month follow-up MR images, but these signal changes resolved within 12-14 months thereafter. The initial tumor volume was significantly greater in patients with disease progression compared with patients with no disease progression (mean volume 4.25 vs 2.0 cm 3 , respectively; p < 0.001). No other variables, including age, tumor pathology, lesion location, previous radiotherapy, KPS score, and GKS maximum and marginal dosage, differed significantly between the 2 groups. There were no variables that significantly correlated with the change in tumor size or that predicted a decrease of more than 50% in volume. Because there was only 1 death, overall survival was not analyzed separately from progression-free survival.
Adverse Radiation Effects
In addition to the 4 patients with definitive clinical and MRI tumor progression, 3 patients (12.5%) had evidence of increased peritumoral edema on T2-weighted MRI. In all 3, the edema subsequently resolved. In no case was there evidence of radiation-induced necrosis or radiosurgery-induced transformation or development of additional neoplasms. Of the 4 patients with tumor progression, the 1 patient who died had persistent increase in both the tumor size and associated edema. Two of the 4 patients had initial decrease in tumor size at 6 months and a later increase in tumor size. The remaining patient had a persistent increase in tumor cyst size after GKS and subsequently required a repeat resection.
Discussion
Predictors of Outcome
In our series, the only significant predictor of tumor progression-free survival was pretreatment tumor size. The mean tumor volume was 4.25 cm 3 in the patients in whom progression occurred compared with 2.0 cm 3 in those in whom the volume remained stable or the tumor regressed. While the number of patients in this series does not allow for a prediction of what size tumor will likely progress, the smallest tumor with progression in our series was 2.8 cm 3 . Brainstem involvement, KPS score, age, previous radiotherapy, peripheral dose, duration of symptoms, and previous progression after surgery were not predictors of disease progression in our patient population. This differs from findings reported from others. 7, 8, 12, 13, 26 We did not specifically investigate the nature of cystic compared with solid pilocytic lesions. Others have reported this to be a significant predictor of progression in that pathology. 12 In the one patient in our series with tumor progression but without brainstem involvement, we documented a significant increase in size of a right frontal cystic lesion. The increase in cyst size prompted repeat surgery. As previously mentioned, there were no significant predictors of the extent of tumor size reduction. Interestingly, in terms of response to GKS, the 5 patients with higher-grade lesions (Grade II or III) did not differ from those patients with pilocytic astrocytomas.
Timing of Tumor Changes After Radiosurgery
The median time until a documented decrease in tumor size was 12.5 months. This duration is consistent with data published in other series. 1, 5, 12, 13, 24, 26 Of note, 1 patient first had a decrease in tumor size only at 46 months but later had complete tumor regression on follow-up MRI. As has been reported elsewhere, some patients experience transient increase in edema that does not necessar- Table 1) had undergone 2 previous resections, with subsequent recurrence of the pilocytic astrocytoma seen in the cerebellar vermis. The second operation was complicated by a CSF leak requiring diversion through a ventriculoperitoneal shunt. The family was presented with the option of additional resection and declined. Gamma Knife surgery was then offered as an alternative. Long-term follow-up imaging demonstrates complete resolution of the enhancing tumor.
ily portend tumor progression. 10, 17, 18 In our series this was present in 3 patients (13%). Such patients can frequently be treated with steroids to reduce signs and symptoms associated with transient radiosurgery-induced edema.
In our series, all patients who demonstrated progression did so within the first 24 months of follow-up. One patient who progressed did so after an initial tumor response to GKS with a 60% reduction in tumor size. Of the remaining 3 other patients with tumor progression, 1 had an initial reduction in tumor size before progression, and 2 never experienced a reduction in tumor size. Others have reported progression at later time points, at least up to 72 months after GKS. 12 It is therefore likely that continued regular surveillance of these lesions is required for at least 10 years after GKS. (See Table 2 for a comparison of this series to other pediatric GKS series.)
Role of Radiosurgery in the Treatment of Pediatric Gliomas
In children with pilocytic astrocytomas, gross-total resection is generally considered curative and is the preferred treatment when possible. However, many lesions located in critical areas, such as the brainstem, thalamus, basal ganglia, hypothalamus, or eloquent cortex, cannot be resected without the risk of considerable morbidity and mortality. Furthermore, small deep residual tumors in noncritical areas may recur, or complete resection may simply not be feasible. In addition, while an increased extent of resection of nonpilocytic gliomas in children is associated with increased survival, surgery is generally not curative for these lesions.
In such cases, additional modalities of chemotherapy, fractionated radiotherapy, and radiosurgery may be beneficial. Fractionated radiotherapy is generally reserved for children greater than 10 years of age given the significant cognitive adverse effects associated with fractionated radiation in younger patients. 4, 14 While neither fractionated radiotherapy nor chemotherapy is curative, both modalities are associated with delayed tumor progression. Various chemotherapeutic regimens are generally used in younger children to delay timing of radiotherapy and its associated adverse cognitive effects.
Gamma Knife stereotactic radiosurgery offers advantages over both chemotherapy and fractionated radiotherapy. In both this series and others, GKS appears to have been associated with increased rates of progressionfree survival and complete tumor response compared with chemotherapy or fractionated radiotherapy. 1, 5, 12 In the present study, such a benefit is apparent in the cases in which the imaging changes of recurrence after resection or persistent growth were reversed following GKS. In addition, the rapid dose falloff from GKS avoids toxicity to surrounding neural structures. This may be of particular significance in the pediatric patient population whose expected lifespan is long. In a recent study by Wolff and colleagues 25 for recurrent brainstem gliomas in pediatric patients, repeat radiotherapy offered the highest response rate and longest progression-free survival compared with a myriad of chemotherapeutic treatments. Given this finding, radiosurgery may be particularly appealing for pediatric patients with small-volume, deep-seated recurrent gliomas after prior radiotherapy. An additional ben- efit of the use of GKS in the pediatric population is the low risk of secondary malignancy. While this series is not equipped to calculate this risk, other studies have demonstrated that the risk is exceedingly low. Indeed the risk appears to be lower than the risk of death associated with general anesthesia. 21 
Study Limitations
Although this is one of the largest radiosurgical series of pediatric glioma patients, the small cohort afforded limited statistical power. Also, the inclusion of 4 patients without histological confirmation of tumor pathology could confound the results. However, in the modern neurosurgical era, patients with clinical and radiological evidence consistent with a brainstem glioma are often treated without a biopsy, much less open resection. In addition, we recognize that the patients included in the current series had generally smaller tumors, which, as such, leads to a selection bias in the results.
Another limitation of the present study is the selection of patients undergoing GKS compared with the overall pediatric glioma patient population. The goal of our series was to demonstrate our experience with GKS for gliomas in children. The patients had evidence of recurrent or residual tumor or tumors that were not considered amenable to resection. We did not attempt to review all pediatric gliomas treated at our institution to characterize the subset of patients who were subsequently referred for GKS. Such an investigation would be interesting, although it is beyond the scope of the present study.
Additionally, the study is limited in that the group of patients is heterogeneous. Our rationale for including all patients was to describe our complete experience in terms of the scope of gliomas treated. The overall experience in the literature with radiosurgical treatment of pediatric gliomas is small, as indicated in the article. Even in our center, which has a broad referral pattern, and in the present series, which spans more than 20 years, these tumors were not abundant. By including all patients, we sought to add to the literature in the most meaningful way. Still, this study is not sufficient to compare the efficacy of treatment of these tumors to the natural histories of the various types of tumors included. We do believe that the imaging and clinical responses seen in the majority of patients are consistent with efficacious treatment. In many cases, the tumors treated had already demonstrated persistent growth despite resection and other treatments. A subsequent reduction in tumor size after GKS in these patients can be viewed as a sign of efficacy.
Conclusions
The management of deep-seated glial tumors in pediatric patients remains a challenge. Other authors have discussed treatment decisions in terms of fractionated radiotherapy or chemotherapy. Unfortunately, for lesions that cannot be fully or even partially resected without posing significant risk to the patient, no modality provides control of all tumors. Through this series and others, however, there is increasing evidence that Gamma Knife treatment can provide reasonable control of residual or recurrent gliomas in these patients as well as preservation of neurological status. Poor outcomes in our series were associated with larger tumor volumes at the time of treatment.
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